A 28-year-old woman presents with irregular menses (4–5 cycles per year), hirsutism in a male-pattern distribution, and acne. On examination, she is overweight (BMI 29 kg/m²). Transvaginal ultrasound confirms polycystic ovaries (≥12 follicles per ovary). The pathophysiologic mechanism marked **A** in the diagram (Insulin Resistance / Hyperinsulinemia) drives hyperandrogenism in this patient primarily through which of the following mechanisms?

Explanation

## Why option 1 is right Insulin resistance with compensatory hyperinsulinemia is a central pathophysiologic feature in PCOS (present in 50–70% of patients, independent of obesity). Hyperinsulinemia acts via insulin receptors and IGF-1 receptors on ovarian theca cells to stimulate androgen production. Simultaneously, hyperinsulinemia suppresses hepatic synthesis of sex hormone-binding globulin (SHBG), which normally binds and inactivates testosterone. The result is increased free, bioavailable testosterone — the direct cause of clinical hyperandrogenism (hirsutism, acne, androgenic alopecia) in PCOS. This dual mechanism is the textbook explanation for how insulin resistance drives the hyperandrogenic phenotype in PCOS. ## Why each distractor is wrong - **Option 2**: While LH is elevated in PCOS and contributes to androgen excess, the primary mechanism of hyperinsulinemia-driven hyperandrogenism is NOT via LH suppression. In fact, hyperinsulinemia may amplify LH action on theca cells, not suppress it. This confuses the secondary endocrine abnormality (elevated LH:FSH ratio) with the insulin-mediated mechanism. - **Option 3**: Adrenal androgen excess (elevated DHEA-S) can occur in PCOS but is NOT the primary mechanism by which insulin resistance drives hyperandrogenism. Insulin resistance acts on the ovary (theca cells), not the adrenal gland. Adrenal involvement is secondary and less consistent than ovarian androgen production. - **Option 4**: While adipose tissue does express aromatase, impaired peripheral conversion of testosterone to estradiol is not the mechanism by which hyperinsulinemia causes hyperandrogenism in PCOS. The problem is excess androgen production (ovarian) and reduced SHBG-mediated clearance, not defective peripheral aromatization. **High-Yield:** Hyperinsulinemia in PCOS acts on the ovary (↑ theca androgen) AND the liver (↓ SHBG) — a dual mechanism that explains clinical hyperandrogenism independent of obesity. [cite: Williams Gynecology 4e; Endocrine Society 2023 Guidelines on PCOS diagnosis and management]